New drug combo aims to protect transplanted hearts

NCT ID NCT03292861

ENROLLING_BY_INVITATION Disease control Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding Thymoglobulin to standard anti-rejection drugs helps prevent complications after a first heart transplant. About 60 adults will receive either standard therapy alone or standard therapy plus five days of Thymoglobulin. Researchers will check for signs of rejection and artery disease over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thymoglobulin (an anti-rejection drug given intravenously)
What this could lead to: If it works, this could reduce the risk of heart transplant rejection and artery damage, helping transplanted hearts last longer.
What could go wrong: This is a small, early-phase study at one center, so results may not apply widely. Thymoglobulin can cause serious side effects like infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure chronic transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART TRANSPLANTATION

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, 90027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.